CMT > Lipids > Flashcards

Lipids Flashcards

(126 cards)

Study These Flashcards
1
Q

3 types of lipids

A
  1. cholesterol
  2. triglycerides
  3. lipoproteins
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what is cholesterol

define/describe

A

essential element of all animal cell membranes and the backbone of steroid hormones and bile acids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what are triglycerides

A

txfr energy from food into cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what are lipoproteins

A
  • transport lipids
  • classified by density
  • apoprotiein is dense
  • triglyceride is less dense
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

7 types of lipoproteins

A
  1. chylomicrons
  2. low-density lipoprotein
  3. high-density lipoprotein
  4. very-low-density lipoprotein
  5. Apolipoprotein B (apoB)
  6. Lipoprotein
  7. non-HDL cholesterol
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

describe chylomicrons

A

least dense
found in blood after fatty meals

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

describe LDL

A

carry most of our cholesterol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

describe VLDL

A

least dense, large
consists mostly of triglycerides that are txfr to cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

describe HDL

A

most dense & smallest
participate in reverse cholesterol transport

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

describe apoB

A
  • protein that carries LDL and helps it bind to the cell wall
  • contributes to atherogenesis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

describe lipoprotein a (lp(a))

A
  • genetically determined subfraction of LDL
  • causal factor in atherosclerosis
  • one-time measurement rec in pts w/ family hx of ASCVD
  • risk enhancing factor favoring early statin tx
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

describe non-HDL cholesterol

A
  • surrogate marker of apoB
  • measured directly, less sensitive to fasting status
  • better predictor of CV risk than LDL
  • non-HDL Cholesterol = TC - HDL
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

which lipid value is most sensitive to fasting?

A

triglycerides

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

which lipoprotein carries the most cholesterol

A

LDL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

which lipoprotein is an independent risk for ASCVD

A

Lp(a)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

which lipoprotein represents all apoB containing particles?

A

non-HDL calculation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

what are the components of a lipid panel?

4

A
  1. total cholesterol
  2. LDL
  3. HDL
  4. triglycerides
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

which components of a lipid panel are measured directly? which are calculated?

A
  1. direct: TC, HDL, triglycerides
  2. calc: LDL
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

equation for TC

A

HDL + VLDL + LDL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

equation for non-HDL cholesterol

A

TC - HDL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

equation for VLDL

& when to use

A

TG / 5

only if TG is < 400

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

equation for LDL

A

TC - HDL - (TG / 5)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

what are benchmarks for LDL levels?

5

A
  • less than 100: optimal
  • 100-129: near optimal/above optimal
  • 130-159: borderline high
  • 160-189: high
  • more than 190: very high
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

what are benchmarks for TC levels?

3

A
  • less than 200: desirable
  • 200-239: borderline high
  • greater than 240: high
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
what are benchmarks for HDL cholesterol? | 2
* less than 40: low * greater than 60: high
26
benchmarks of triglycerides? | 4
* less than 150: normal * 150-199: borderline high * 200-499: high * more than 500: very high
27
what is the goal of lipid treatment? when does this goal change?
* to reduce LDL * when triglycerides are greater than 500
28
what is the risk of treating when triglycerides are greater than 500?
pancreatitis
29
# Atherosclerosis associated with?
* high LDL * low HDL
30
# Atherosclerosis pathophys
plaque w/ large amounts of cholesterol build up in arterial walls
31
# Atherosclerosis mostly asx until?
rupture or vessel occlusion (MI or CVA)
32
# Familial Hypercholesterolemia associated with which genetic components? | 3
1. defective LDL receptors 2. genetic mutations of apo B 3. gain of function mutation of PCSK9
33
# Familial Hypercholesterolemia which lipid is usually elevated?
* total cholesterol
34
# Familial Hypercholesterolemia describe clinical manifestation of heterozygous pts
* up to 3x normal levels of LDL * LV disease begins in 30s or 40s
35
# Familial Hypercholesterolemia describe clinical manifestation of homozygous pts
* extremely high LDL (up to 8x normal) * atherosclerosis in childhood * may require plasmapheresis to remove cholesterol
36
# Familial Chylomicronemia AKA | 3 things
1. Lipoprotein Lipase Deficiency (LPLD) 2. Fredrickson Type 1 Hyperlipoproteinemia 3. Familial Hypertriglyceridemia
37
# Familial Chylomicronemia caused by?
abnormality of LPL that is responsible for ability of itssues to take up triglycerides (TG) from chylomicrons
38
# Familial Chylomicronemia characterized by?
hypertriglyceridemia
39
# Familial Chylomicronemia complications | 2
* recurrent pancreatitis * hepatosplenomegaly
40
# Familial Chylomicronemia important to abstain from?
EtOH
41
# Dysbetalipoproteinemia elevated levels of?
reminant lipoproteins
42
# Dysbetalipoproteinemia associated with?
premature ASCVD
43
# Familial Combined Hyperlipidemia most commonly affected genes? | 3
* LDLR * APOB * PCSK9
44
Conditions that affect lipids | AKA- secondary causes of dyslipidemia- 11
1. metabolic syndrome 2. type 2 diabetes 3. uncontrolled hyperglycemia 4. obesity 5. hypothyroidism 6. liver disease 7. renal disease 8. corticosteroid use 9. progestin use 10. anabolic steroid use 11. alcohol use/abuse
45
conditions that increase TC | 10
1. obesity 2. uncontrolled DM 3. hypothyroidism/Cushing 4. nephrotic syndrome 5. CKD 6. obstructive liver disease 7. corticosteroid use 8. OCPs 9. Diuretics 10. Beta Blockers
46
conditions that decrease TC | 3
1. hyperthyroidism 2. cirrhosis 3. malignancy
47
factor that increases LDL | 1
1. alcohol use
48
conditions that decrease HDL | 4
1. obesity 2. sedentary lifestyle 3. metabolic syndromes 4. beta blockers
49
conditions that increase triglycerides | 6
1. DM 2. alcohol use 3. nephrotic syndrome 4. CKD 5. OCP 6. diuretics
50
you are treating a pt for high cholesterol. Current LDL is non-calculable, other values are: * TG > 450 * HDL: 40 * TSH: 10 (normal < 4) * HgA1C: 9.8 why is her cholesterol not at goal in spite of compliance with cholesterol medications?
must correct DM and TSH
51
Clinical Presentation | 4- but really labs are best dx tool
1. eruptive xanthomas/xanthelasma 2. tendinous xanthomas 3. lipemia retinalis 4. corneal arcus
52
Screening Guidelines Children
* selective screening for children age > 2 y/o with family hx, lipid disorder, or premature ASCVD * first screen between ages 9-11 and again between 17-21
53
Screening Guidelines Adults
* first at age 20 if not done as a child * every 5 years for those at low risk after age 35 (men) or 45 (women) * more often screenings based on relative risk
54
Screening Guidelines for Older Adults
* screening not recommended for those over age 75
55
Describe Pooled Cohort Equations
* estimates 10 year risk of MI, CVA, CV death * does over-estimate risk of middle/higher SES pts * separate calculator for white/black pts
56
Pooled Cohort Equation risk levels defined
10 year risk is.... * less than 5%: low * 5-7.5%: borderline * 7.5-20%: intermediate * more than 20%: high
57
Risk enhancing factors- basically who will benefit the most from therapy? | 12
1. family hx of premature disease 2. metabolic syndrome 3. chronic inflammatory conditions 4. high risk race/ethnicity 5. elevated hsCRP 6. elevated apo B 7. primary hypercholesterolemia 8. CKD 9. hx of pre-eclampsia or premature menopause 10. presistently high TG 11. elevated apo(a) 12. low ankle brachial index
58
# Cardiac Calcium Score is the...... | best....
single best test for additional risk stratification
59
# Cardiac Calcium Score what type of imaging?
noncontrast cardiac gated CT
60
# Cardiac Calcium Score repeat how often?
every 3 to 7 yrs based on risk
61
# Cardiac Calcium Score how to interpret a cardiac calcium score | 5 categories
* 0: no evidence of CAD * 1-10: minimal evidence of CAD * 11-100: mild evidence of CAD * 101-400: moderate evidence of CAD * 400 + : severe evidence of CAD
62
A pt with which of the following characteristics will a cardiac calcium score be most useful in a shared decision-making model? * aged 75 * intermediate 10-year risk of heart disease * LDL of 194 * type 2 DM * smoker
intermediate 10 year risk of heart disease
63
The Pooled Cohort Equation is used to estimated the 10-year risk of heart disease or stroke for an individual. The risk is reported to be 10%. What risk category is the result? * borderline * high * intermediate * low
intermediate
64
# CV Disease Prevention what is primary prevention
* refers to therapy in persons with no known cardiovascular disease
65
# CV Disease Prevention what is secondary prevention
* therapy in persons with known CV disease
66
# CV Disease Prevention At what age do you stop primary prevention?
75
67
# CV Disease Prevention What shouldn't you use as primary prevention in pregnant women?
statins
68
# CV Disease Prevention When do you consider lifestyle factors and drug therapies in someone with 0-1 risk factors?
* Lifestyle changes: LDL > 160 * Drug therapies: LDL > 190
69
# CV Disease Prevention When do you consider lifestyle factors and drug therapies in someone with 2+ risk factors?
* Lifestyle: LDL > 130 Drug therapies * 10-year risk 10-20%: LDL > 130 * 10-year-risk < 10%: LDL > 160
70
# CV Disease Prevention When do you consider lifestyle factors and drug therapies in someone with CHD?
* Lifestyle: LDL > 100 * Drug Therapies: LDL > 130
71
# CV Disease Prevention Who gets high intensity statins for primary prevention?
* LDL > 190 * Age 40-75 with diabetes AND risk enhancing factors or 10-year risk >20% * Age 40-75 without diabetes with LDL 70-189 and intermediate or high risk with additional risk factors
72
# CV Disease Prevention Who gets moderate intensity statins for primary prevention?
* Age 40-75 with diabetes * Age 40-75 without diabetes with LDL 70-189 and intermediate or high risk
73
# CV Disease Prevention Descisions to continue statin therapies in pts older than 75 y/o should be based on: | 4 things
1. functional status 2. life expectancy 3. comorbidities 4. pt preference
74
# CV Disease Prevention who is very high risk? | 4 things
1. ACS within past 12 mo 2. MI other than event listed above 3. hx of ischemic stroke 4. symptomatic PAD
75
# CV Disease Prevention what is considered high risk> | 8 things
1. > 65 y/o 2. heterozygous familial hypocholesterolemia 3. DM 4. hypertension 5. CKD 6. current smoker 7. CHF 8. LDL >100 with statin and ezetimibe
76
# CV Disease Prevention who gets a statin in secondary prevention?
EVERYONE
77
# Lipid Treatment What lifestyle changes should be made? what lipid does component act on? | 5 general measures
1. exercise (increases HDL) 2. wt loss (decreases LDL, increases HDL) 3. tobacco cessation (increases HDL) 4. modest alcohol use (increases HDL) 5. Aspirin (not rec for all)
78
# Lipid Treatment after how long should you recheck lipids after lifestyle changes?
4-6 wks
79
# Lipid Treatment Desired dietary intake for lifestyle changes?
1. total fat 25-30% of cals 2. saturated fats < 7% of cals 3. dietary cholesterol < 200 mg/d 4. 20-30g of soluble fiber daily 5. 2g of plant stanols and sterols daily 6. antioxidants
80
# Lipid Treatment which diet is most moften recommended for cholesterol reduction?
mediterranean
81
A 45 y/o woman with no risk factors for CHD is found to have cholesterol levels of 165 mg/dL. What nutrition advice should you give? 1. abstain from all alcohol 2. begin a fish oil supplement 3. cut carbohydrate intake to < 30% of cals 4. decrease saturated fat to < 15% of cals 5. increase fiber to 20g daily
increase fiber to 20g daily
82
Which of the following "natural" interventions has not been proven to reduce cholesterol? 1. almonds 2. walnuts 3. increased fiber 4. Co-Q 10 5. Plant stanols 6. Red-yeast rice extract
Plant stanols
83
# Lipid Treatment first, second, third line for hyperlipidemia?
1. statins 2. ezetimibe 3. PCSK9 inhibitors
84
# Lipid Treatment first, second, third line for hypertriglyceridemia?
1. fibrates 2. niacin 3. fish oil
85
# Lipid Treatment names for fish oil tx
1. icosapent ethyl (vascepa) 2. omega-3-acid ethyl esters (lovaza)
86
# Lipid Treatment Benefits of fish oil tx
* reduce TG up to 30%
87
# Lipid Treatment dosage for fish oils | CAD tx vs TG
1. 1g/d for CAD 2. 2-4g/d for TG reduction
88
# Lipid Treatment Contraindications of fish oils
1. fish/shellfish allergy 2. increased bleeding risk 3. discontinue for surgery
89
# Lipid Treatment benefit of niacin (niaspan)?
* reduces LDL 15-25% * increases HDL 25-35%
90
# Lipid Treatment what to take 1 hr before Niacin?
Aspirin or NSAID
91
# Lipid Treatment Contraindications of Niacin?
* caution with cyclosporine, macrolides, anti-fungals, and other CYP metabolites
92
# Lipid Treatment names for fibrates that might be prescribed?
1. gemifibrozil (Lopid) 2. fenofibrate (Tricor, Triglide, Lipofen)
93
# Lipid Treatment benefits of fibrates
* reduce TG 40% * reduce LDL 10-15% * Increase HDL 15-20%
94
# Lipid Treatment contraindications of fibrates?
1. impaired renal function 2. caution w/ cyclosporine, macrolides, anti-fungals, and CYP450 metabolites
95
# Lipid Treatment MOA of statins
* inhibit the rate-limiting enzyme in the formation of cholesterol in the liver and increases hepatic LDL receptors
96
# Lipid Treatment risks of statins | 6
1. myalgias 2. CK elevations 3. myositis 4. rhabdomyolysis 5. elevated transaminases 6. DM development
97
# Lipid Treatment contraindications of statins?
* Liver function * niacin, fibrates, EES, anti-fungals, nefazodone, cyclosporin
98
# Lipid Treatment by how much do low intensity statins reduce LDLs? which meds/doses are low intensity?
1. < 30% 2. Pravastatin, 10-20mg 3. Lovastatin, 20mg
99
# Lipid Treatment by how much do moderate intensity statins reduce LDLs? which meds/doses are moderate intensity?
1. 30-50% 2. Pitavastatin, 2-4mg 3. Simvastatin, 20-40mg 4. Pravastatin, 40-80mg 5. Atovastatin, 10-20mg 6. Rosuvastatin, 5-10mg
100
# Lipid Treatment by how much do high intensity statins reduce LDLs? which meds/doses are high intensity?
* reduce LDLs by ~50% 1. Atovastatin, 40-80mg 2. Rosuvastatin, 20-40mg
101
which of the following statin medications and doses is high intensity intervention? 1. Atorvastatin, 40mg 2. Lovastatin, 20mg 3. Pravastatin, 40mg 4. Simvastatin, 40mg 5. Rosuvastatin, 10mg
Atorvastatin, 40mg
102
Select all statins that could be used to reduce LDL by 35-50% 1. atorvastatin, 40mg 2. atorvastatin, 80mg 3. rosuvastatin, 10mg 4. rosuvastatin, 20mg 5. simvastatin, 10mg
rosuvastatin 10 mg
103
# Lipid Treatments what meds are bile acid sequestrants?
* cholestryamine (Questran) * colesevelam (Welchol) * colestipol (Colestid)
104
# Lipid Treatments moa of bile acid sequestrants
binds bile acids in the intestine which increases bile acid synthesis and LDL receptor activity
105
# Lipid Treatments benefits of bile acid sequestrants?
1. reduces LDL by 15-25% 2. safe in pregnancy 3. can use with liver disease
106
# Lipid Treatments risks of bile acid sequestrants?
TG may increase
107
# Lipid Treatments contraindications of bile acid sequestrants? | NOT A MED
TG >500 mg/dL
108
# Lipid Treatments what med is a cholesterol absorption inhibitor?
ezetimibe (zetia) 10 mg daily
109
# Lipid Treatments MOA of ezetimibe
inhibits intestinal absorption of dietary and biliary cholesterol by inhibiting cholesterol transport. can use as monotherapy or add to statin
110
# Lipid Treatments benefits of ezetimibe
* reduced LDL 15-20% * reduces hsCRP * well tolerated, QD
111
# Lipid Treatments contraindications of ezetimibe
liver failure
112
# Lipid Treatments which meds are PCSK9 inhibitors
* alirocumab (Praluent) * evolocumab (Repatha)
113
# Lipid Treatments moa of PCSK9 inhibitors
human monoclonal antibodies that inhibit LDL receptor degradation use as a monotherapy or with statins
114
# Lipid Treatments benefits of PCSK9 inhibitors
* decrease LDL 50-60% * decrease Lp(a) 20-30%
115
# Lipid Treatments which meds are adenosine triphosphate-citrate lyase inhibitors? (ACL)
Bempedoic Acid (nexletol) Bempedoic Acid + ezetimibide (Nexlizet)
116
# Lipid Treatments moa of ACL inhibitors
* targets cholesterol synthesis in the liver (two steps upstream of statins) * up regulation of LDL receptors in the liver
117
# Lipid Treatments benefits of ACL inhibitors
* lowers LDL by 17-20% * combo w/ ezetimibe: 38%
118
# Lipid Treatments contraindications of ACL inhibitors
* not to be used with simvastatin 20mg or pravastatin 40mg
119
# Lipid Treatments which med is angiopoietin-like 3 (ANGPTL3) inhibitor?
evinacumab
120
# Lipid Treatments moa of ANGPTL3 Inhibitors
* monoclonal antibody * activates lipoprotein lipase and endothelial lipase to increase lipid metabolism
121
# Lipid Treatments benefits of ANGPTL3 inhibitors
1. reduces TG 2. reduces non-HDL cholesterol 3. LDL redution by 49%
122
# Lipid Treatments which med is small interfering RNA?
inclisiran (leqvio)
123
# Lipid Treatments moa of small interfering rna
silences RNA involved in the synthesis of PCSK9 that controls synthesis of LDL cell surface receptors
124
# Lipid Treatments indications of inclisiran
1. maximally tolerated statin dose 2. clinical CV disease 3. pts with heterozygous familal hypercholesterolemia
125
# Lipid Treatments use small interfering RNA meds in combo with? to do what?
* adjunct to statins * to address LDL
126
# Lipid Treatments how often to check lipids? how often after desired levels achieved?
* check 12 wks after therapy initiation * after at goal: check anually
CMT
flashcards
Decks in class (78)
# Cards
Brainscape helps you reach your goals faster, through stronger study habits.
© 2026 Bold Learning Solutions. Terms and Conditions